- Conditions
- Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Interventions
- NKTR-255, Cetuximab
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 2,726
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
- Interventions
- CI-1040
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Blendora, California • Glendale, California + 23 more
- Conditions
- Barrett Esophagus, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Reflux Disease, Metaplasia
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Swallowable Sponge Cell Sampling Device
- Other · Device
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration, Toripalimab
- Procedure · Other · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Johns Creek, Georgia
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
- Interventions
- MDX2001
- Drug
- Lead sponsor
- ModeX Therapeutics, An OPKO Health Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more
- Conditions
- Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
- Interventions
- HistoSonics Edison System
- Device
- Lead sponsor
- HistoSonics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 33
- States / cities
- Fullerton, California • Los Angeles, California • Mission Viejo, California + 26 more
- Conditions
- Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Interventions
- Anti-CD19 CAR PBL
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Interventions
- PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Hepatocellular Carcinoma, Cirrhosis
- Interventions
- Namenda
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
- Interventions
- Ibrutinib, Durvalumab
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Radiation Therapy, Tremelimumab, Durvalumab, Surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
- Interventions
- MT-4561
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
- Interventions
- Blood samples
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,865 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2024
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota + 1 more
- Conditions
- Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
- Interventions
- Gemcitabine, Cisplatin, Durvalumab, Yttrium-90
- Drug · Radiation
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Bladder Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Transitional Cell Carcinoma of the Bladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis, pharmacological study, cisplatin
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Advanced Neoplasms
- Interventions
- E7386
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • Pasadena, California + 3 more
- Conditions
- Breast Carcinoma, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Head and Neck Neoplasm, Malignant Nervous System Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm, Skin Neoplasm, Soft Tissue Neoplasm, Central Nervous System Neoplasm, Endocrine Gland Neoplasms
- Interventions
- Serious Illness Conversation Program training, ACS Geriatric Surgery Verification Program Implementation
- Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- Oral repotrectinib (TPX-0005)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 49
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 36 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Stereotactic Body Radiation Therapy (SBRT)
- Combination Product
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B
- Interventions
- Ultrasound or abbreviated MRI
- Diagnostic Test
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Tahlequah, Oklahoma
- Conditions
- Liver Cancer
- Interventions
- iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
- Drug · Other
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
- Conditions
- Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor, Colorectal Cancer, Gastric Cancer, Primary Peritoneal Carcinoma, Mesothelioma
- Interventions
- nanoliposomal irinotecan
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Stony Brook, New York
- Conditions
- Adenoid Cystic Carcinoma, Colorectal Cancer
- Interventions
- RGT-61159, lenvatinib
- Drug
- Lead sponsor
- Rgenta Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more